Mechanisms responsible for signaling and functional defects

Journal of Immunotherapy

Volumn 21, Issue 4, 1998, Pages 295-306

  Reichert, Torsten E ^a   Rabinowich, Hannah ^a,b   Johnson, Jonas T ^a,b   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

FasL; Head and neck carcinoma; Signaling defects; T cell defects; Tumor associated lymphocytes; Tumor induced immunosuppression; Tumors

Indexed keywords

CALCIUM ION; CD3 ANTIGEN; FC RECEPTOR; MESSENGER RNA; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE; T LYMPHOCYTE RECEPTOR;

ADVANCED CANCER; APOPTOSIS; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CELL ISOLATION; CONFERENCE PAPER; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LEUKEMIA CELL LINE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0031846804     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199807000-00007     Document Type: Article

References (33)

1. Whiteside TL. Tumor infiltrating lymphocytes in human malignancies. Austin: Landes, 1994.
2. Whiteside TL, Parmiani G. Tumor-infiltrating lymphocytes: their phenotype, function and clinical use. Cancer Immunol Immunother 1994;39:15-21.
3. Miescher SL, Whiteside TL, Carrell S, Von Fliedner V. Functional properties of tumor infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supematants on proliferative responses of lymphocytes. J Immunol 1996;136: 1899-907.
4. Alexander JP, Kudoh S, Melsop KA, et al. T cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 1993;53:1380-7.
5. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, Von Fliedner V. Preferential clonogenic deficit of CD8-positive T lymphocytes infiltrating human solid tumors. Cancer Res 1988;48:6992-99.
6. Ochoa AC, Longo DL. Alteration of signal transduction in T cells from cancer patients. In: DeVita VT, Heilman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: JB Lippincott Co., 1995:43-54.
7. lck in T cells infiltrating human renal cell carcinoma. Cancer Res 1993;53:5613-6.
8. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL. Alteration in expression and function of signal transducing proteins in tumor-associated T and NK cells in patients with ovarian carcinoma. Clin Cancer Res 1996;2:161-73.
9. Zea AH, Cutri BD, Longo DL, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995;1:1327-35.
10. Matsuda M, Petersson M, Lenkei R, et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 1995;61:765-72.
11. Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Ini J Cancer 1996;67:333-8.
12. Rabinowich H, Suminami K, Reichert T, et al. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1994;68: 276-84.
13. He DS, Snyderman CH, Gollin SM, et al. Biology, cytogenetics and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 1989;49:5167-75.
14. Snyderman CS, He DS, Johnson JT, D’Amico F, Barnes L, Whiteside TL. Functional and phenotypic analysis of lymphocytes isolated from tumors and lymph nodes of patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1991;117:899-905.
15. Rabinowich H, Banks M, Reichert T, Logan TF, Kirkwood JM, Whiteside TL. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after IL-2 therapy. Clin Cancer Res 1996;2:1263-74.
16. Chen K, Demetris AJ, Van Thiel DH, Whiteside TL. Double immunoenzyme staining method for analysis of tissue and blood lymphocyte subsets with monoclonal antibodies. Lab Invest 1987; 56:114-9.
17. Suminami Y, Elder EM, Lotze MT, Whiteside TL. In situ interleukin-4 gene expression in cancer patients treated with genetically-modified tumor vaccine. J Immunother 1995; 17:238-48.
18. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991;145:185-92.
19. Vujanovic NL, Nagashima S, Herberman RB, Whiteside TL. Non-secretory apoptotic killing by human natural killer cells. J Immunol 1996;157:1117-26.
20. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology-analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997;27:1-20.
21. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
22. Cianciolo GL, Copeland TD, Oroszlan S, Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 1985;230:453-5.
23. Uotila P. The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol Immunother 1996;43:1-9.
24. Aoe T, Okamoto Y, Saito T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 1995;181:1881-6.
25. Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing ζ molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996;26: 1308-13.
26. Li X, Liu J, Park JK, et al. T cells from renal cell carcinoma patients exhibit an abnormal pattern of 6B-specific DNA binding activity: a preliminary report. Cancer Res 1994;54:5424-9.
27. Rabinowich H, Reichert TE, Kashii Y, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas Ligand-expressing ovarian carcinoma cells: implications for altered expression of TCR in tumor-associated lymphocytes. J Clin Investigation (in press).
28. Beilgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 277:630-2.
29. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
30. O’Connell J, O’Sullivan GC, Collins JK, Shanahan F. The Fas counterattack-Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
31. Strand S, Hofmann WJ, Hug WJ, et al. Lymphocyte apoptosis induced by CD95 (APO-l/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nature Med 1997;2:1361-6.
32. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-l/CD95) ligand-implications for tumor immune escape. Science 1996;274:1363-6.
33. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinoma express Fas ligand. Cancer Res 1997;57:1007-12.